These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 446504)

  • 1. Antiandrogens in the treatment of prostatic cancer.
    Bracci U
    Eur Urol; 1979; 5(5):303-6. PubMed ID: 446504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of symptomatic metastatic prostatic cancer with cyproterone acetate versus orchiectomy: a prospective randomized trial.
    Ostri P; Bonnesen T; Nilsson T; Frimodt-Møller C
    Urol Int; 1991; 46(2):167-71. PubMed ID: 1711250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced prostatic carcinoma with cyproterone acetate and orchiectomy--5-year follow-up.
    Giuliani L; Pescatore D; Giberti C; Martorana G; Natta G
    Eur Urol; 1980; 6(3):145-8. PubMed ID: 7371659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orchiectomy combined with cyproterone acetate or prednisone in the treatment of advanced prostatic carcinoma. A randomized clinical and endocrine study.
    Sander S; Nissen-Meyer R; Aakvaag A
    Scand J Urol Nephrol; 1982; 16(3):193-7. PubMed ID: 6219455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial.
    Jacobi GH; Altwein JE; Kurth KH; Basting R; Hohenfellner R
    Br J Urol; 1980 Jun; 52(3):208-15. PubMed ID: 7000222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cancers of the prostate and cyproterone acetate. Value of blood testosterone and PSA levels for treatment surveillance].
    Aubert J; Dore B; Irani J; Bon D
    J Urol (Paris); 1990; 96(8):431-5. PubMed ID: 1707083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urethral obstruction secondary to carcinoma of prostate: response to endocrine treatment.
    Varenhorst E; Alund G
    Urology; 1985 Apr; 25(4):354-6. PubMed ID: 3157256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of orchiectomy, oestrogens and cyproterone-acetate on the antithrombin-III concentration in carcinoma of the prostate.
    Varnehorst E; Wallentin L; Risberg B
    Urol Res; 1981; 9(1):25-8. PubMed ID: 6455833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial.
    Bullock MJ; Srigley JR; Klotz LH; Goldenberg SL
    Am J Surg Pathol; 2002 Nov; 26(11):1400-13. PubMed ID: 12409716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate.
    Varenhorst E; Wallentin L; Carlström K
    Scand J Urol Nephrol; 1982; 16(1):31-6. PubMed ID: 6211762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW; Uitterlinden P; de Jong FH
    Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Predictive value of clinical, biochemical, hormonal and histologic parameters of the endocrine response in prostatic adenocarcinoma].
    Burgos FJ; Maganto E; Jiménez M; Mayayo T; Allona A; Mateos A; Escudero A; Romero-Aguirre C
    Actas Urol Esp; 1988; 12(6):500-6. PubMed ID: 3232555
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapy of prostatic cancer with cyproterone acetate].
    Maier U
    Wien Klin Wochenschr; 1988 Jan; 100(1):16-9. PubMed ID: 2964127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer.
    Barradell LB; Faulds D
    Drugs Aging; 1994 Jul; 5(1):59-80. PubMed ID: 7919640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
    Schroeder FH; Lock TM; Chadha DR; Debruyne FM; Karthaus HF; de Jong FH; Klijn JG; Matroos AW; de Voogt HJ
    J Urol; 1987 May; 137(5):912-8. PubMed ID: 2952810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidental prostatic carcinoma: four-year follow-up after treatment with cyproterone acetate.
    Di Silverio F; Sciarra F; D'Eramo G; Tenaglia R
    Eur Urol; 1990; 18(4):263-6. PubMed ID: 2149704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
    Mahler C; Verhelst J; Denis L
    Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of prostatic carcinoma with cyproterone acetate.
    Tveter KJ; Otnes B; Hannestad R
    Scand J Urol Nephrol; 1978; 12(2):115-8. PubMed ID: 694435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The treatment of prostatic carcinoma with cyproterone acetate].
    Tsvetkov M; Mladenov D; Kumanov Kh
    Khirurgiia (Sofiia); 1996; 49(1):12-5. PubMed ID: 8975080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R
    J Urol; 1986 Sep; 136(3):624-31. PubMed ID: 2942707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.